Open AccessTargeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity
Author(s) -
Gloria Ciniero,
Francesco Gentile,
Ahmed H. Elmenoufy,
Emeline CrosPerrial,
F. G. West,
Michael Weinfeld,
Marco Agostino Deriu,
Lars Petter Jordheim,
Jack A. Tuszyński
Publication year - 2021
Publication title -
biomedical science and engineering
Language(s) - English
Resource type - Journals
ISSN - 2531-9892
DOI - 10.4081/bse.2021.164
Subject(s) - ercc1 , drug resistance , cancer , cancer research , cancer cell , biology , drug , pharmacology , gene , chemistry , nucleotide excision repair , dna repair , genetics
New disruptors of the ERCC1-XPF interaction interaction have a synergistic effect with traditional NER inhibitors, in p53 positive cells. Furthermore, the synergy can be resumed in p53 negative cells upon reactivation of the TP53 gene.